Hydantoin thiohydantoin pyrimidinedione and thioxopyrimidinone derivatives preparation method and use as medicines
申请人:Societe de Conseils de Recherches et d' Applications Scientifiques
公开号:US06759415B1
公开(公告)日:2004-07-06
The invention concerns compounds for treating pathological conditions or diseases wherein one (or several) somatostatin receptors is (are) involved, corresponding to general formula (I) wherein: R1 represents in particular a carbocyclic or heterocyclic aryl radical optionally substituted or a non-aromatic heterocyclic radical optionally substituted; R2 represents H, alkyl or aryl optionally substituted; R3 represents H or —(CH2)p—Z3, Z3 representing in particular alkyl, cycloalkyl, bis-arylalkyl or di-aryalkyl, —Y1—(CH2)p-phenyl-(X1)n, carbocyclic or heterocyclic aryl optionally substituted, a non-aromatic heterocyclic radical optionally substituted, X1, every time it is present, being independently selected in particular among the radicals H, Cl, F, Br, I, CF3, NO2, OH, NH2, CN, N3, —OCF3, alkyl, alkoxy, —S-alkyl, —(CH2)p—NH2, —(CH2)p—NH-alkyl, —(CH2)p—N-alkyl; Y1 represents O, S, NH or is not present; R4 represents —(CH2)p—Z4, Z4 representing in particular amino, alkylamino, N,N-dialkylamino; R5 represents in particular H or alkyl; X represents O or S; p each time it is present is independently 0 or an integer ranging between 1 and 6; q each time it is present is independently an integer between 1 and 5; n represents 0 or 1; provided that when n represents 0, m represents 1, 2 or 3, and when n represents 1, m represents 0 or 1.
该发明涉及用于治疗涉及一个(或多个)生长抑素受体参与的病理状况或疾病的化合物,对应于一般式(I),其中:R1特指一个可选取代的碳环或杂环芳基基团或一个可选取代的非芳香杂环基团;R2代表H,烷基或可选取代的芳基;R3代表H或—(CH2)p—Z3,Z3特指特定的烷基、环烷基、双芳基烷基或二芳基烷基,—Y1—(CH2)p-苯基-(X1)n,可选取代的碳环或杂环芳基,可选取代的非芳香杂环基团,X1每次出现时,可独立地从H、Cl、F、Br、I、CF3、NO2、OH、NH2、CN、N3、—OCF3、烷基、烷氧基、—S-烷基、—(CH2)p—NH2、—(CH2)p—NH-烷基、—(CH2)p—N-烷基中特选取;Y1代表O、S、NH或不存在;R4代表—(CH2)p—Z4,Z4特指特定的氨基、烷基氨基、N,N-二烷基氨基;R5特指H或烷基;X代表O或S;p每次出现时可独立地为0或介于1和6之间的整数;q每次出现时可独立地为介于1和5之间的整数;n代表0或1;但是当n代表0时,m代表1、2或3,当n代表1时,m代表0或1。